• Mashup Score: 8

    Evaluation of metabolic tumor volume (MTV) changes using amino acid PET has become an important tool for response assessment in brain tumor patients. MTV is usually determined by manual or semiautomatic delineation, which is laborious and may be prone to intra- and interobserver variability. The goal of our study was to develop a method for automated MTV segmentation and to evaluate its performance for response assessment in patients with gliomas. Methods: In total, 699 amino acid PET scans using the tracer O -(2-[18F]fluoroethyl)-l-tyrosine (18F-FET) from 555 brain tumor patients at initial diagnosis or during follow-up were retrospectively evaluated (mainly glioma patients, 76%). 18F-FET PET MTVs were segmented semiautomatically by experienced readers. An artificial neural network (no new U-Net) was configured on 476 scans from 399 patients, and the network performance was evaluated on a test dataset including 223 scans from 156 patients. Surface and volumetric Dice similarity coeffi

    Tweet Tweets with this article
    • New AI tool for PET imaging allows for high-quality, fully automated evaluation of #brainTumors https://t.co/IVVd5LoW5P https://t.co/ORSOEnT1c8

  • Mashup Score: 0

    SEER*Explorer provides access to SEER cancer statistics and detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number of cancer sites, by stage and histology.

    Tweet Tweets with this article
    • Non-malignant #BrainTumors become more common with age. Past age 34, women are more likely than men to be diagnosed with non-malignant brain tumors. Visit SEER*Explorer to learn more: https://t.co/24eMFmpZt6 #BrainTumorThursday https://t.co/3yrpyxG2Ub

  • Mashup Score: 3

    By Matthew Stenger Posted: 7/17/2023 12:40:00 PM Last Updated: 7/17/2023 11:59:20 AM In a small phase II trial reported in The New England Journal of Medicine, Priscilla K. Brastianos, MD, and colleagues found that the BRAF-MEK inhibitor combination of vemurafenib and cobimetinib produced an objective…

    Tweet Tweets with this article
    • RT @ASCOPost: Vemurafenib Plus Cobimetinib in Newly Diagnosed Patients With Papillary Craniopharyngiomas https://t.co/S87GmHduyZ #btsm #bra…

    • Vemurafenib Plus Cobimetinib in Newly Diagnosed Patients With Papillary Craniopharyngiomas https://t.co/S87GmHduyZ #btsm #braintumors #oncology